The impact on sexual functioning of chemotherapy-induced menopause in women with breast cancer

Cancer Nursing

Volumn 25, Issue 1, 2002, Pages 57-65

  Rogers, Megan ^a   Kristjanson, Linda J ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Breast cancer; Chemotherapy; Menopause; Sexual functioning

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; SEX HORMONE;

AMENORRHEA; BIBLIOGRAPHIC DATABASE; BODY IMAGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; DRUG DOSE; DRUG EFFECT; FEMALE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LIBIDO; MEDLINE; MENOPAUSE; OVARY FUNCTION; PRIORITY JOURNAL; PSYCINFO; REVIEW; SEXUAL FUNCTION; SIDE EFFECT;

EID: 0036158198     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200202000-00011     Document Type: Review

References (92)

1. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning
2. Sexual functioning in women with breast cancer after treatment with adjuvant therapy
3. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
4. Menopause as an issue for women with breast cancer
5. Estrogen-replacement therapy in younger women with breast cancer
6. Sexual functioning after breast cancer: A conceptual framework for future studies
7. Quality of life in breast cancer. Part 1: Physical and social well being
8. Adjuvant chemotherapy for breast carcinoma. Psychological implications
9. Effects of cancer on the sexuality and fertility of women
10. The importance of sexual rehabilitation after breast cancer surgery treatment
11. Sexuality and body image in younger women with breast cancer
12. The impact of breast cancer on sexuality, body image and intimate relationships
13. Side effects of adjuvant chemotherapy: Perceptions of node-negative breast cancer patients
14. Psychological morbidity and quality of life in Australian women with early stage breast cancer: A cross-sectional survey
15. Characteristics of women at risk for psychosocial distress in the year after breast cancer
16. Breast cancer & psychosexual sequelae: Implications for remediation
17. Sexual functioning and morbidity among cancer survivors
18. Impact of adjuvant therapy on the quality of life in women with node positive operable breast cancer
19. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer
20. Psychosocial aspects of mastectomy. The women's perspective
21. Predictors of sexual health in women after a breast cancer diagnosis
22. Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls
23. Sexual function as a quality of life issue: The impact of breast cancer treatment
24. A neglected issue: The sexual side effects of current treatments for breast cancer
25. Sex after chemotherapy
26. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality
27. Sexuality in women receiving chemotherapy for breast cancer
28. Breast cancer: Psychosocial consequences for the patient
29. The sexual and intimate consequences of breast cancer treatment
30. Psychosexual rehabilitation and exenterative surgery
31. Sexuality and women in breast cancer
32. Psychometric characteristics of individuals with sexual dysfunction and their partners
33. Sex therapy and mastectomy
34. Body image in women treated for breast cancer
35. Psychosocial and sexual impact of diagnosis and treatment of breast cancer
36. Sexuality and breast cancer
37. Psychological outcomes of different treatment policies in women with early breast cancer outside clinical trials
38. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life after surgery?
39. The impact of breast conserving treatment and mastectomy on the quality of life of early stage breast cancer patients: A review
40. Mastectomy versus breast conservation surgery: Mental health effects at long-term follow-up
41. Effects of mastectomy versus lumpectomy on emotional adjustment to breast cancer. A prospective study of the first year post surgery
42. Psychological outcomes of lumpectomy versus mastectomy in the treatment of breast cancer
43. Women's perception. Breast cancer treatment and sexuality
44. Sexuality & cancer
45. Sexual dysfunction in treated breast cancer patients
46. Natural menopause and ovarian toxicity associated with breast cancer
47. Breast cancer in young women: Effects of chemotherapy on ovarian function, fertility, and birth defects
48. Ovarian failure and cancer treatment: Incidence and interventions for the premenopausal women
49. Endocrine profile in breast cancer patients receiving chemotherapy
50. Amenorrhea following chemotherapy for breast cancer: Effect on disease-free survival
51. Comments on the development of amenorrhea caused by myeloran in cases of chronic myelosis
52. Chlorambucil-prednisolone therapy for disseminated breast carcinoma
53. Prospects for fertility after cancer chemotherapy
54. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents
55. Cytotoxic-induced ovarian failure in women with Hodgkin's disease
56. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
57. Effects of cancer chemotherapy on gonadal function and reproductive capacity
58. Cyclophosphamide induced ovarian failure
59. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer
60. Systemic adjuvant therapy of breast cancer
61. Risk of menopause during the first year after breast cancer diagnosis
62. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients
63. Gonadal dysfunction
64. Nonhormonal alternatives for the management of early menopause in younger women with breast cancer
65. Menopause: A problem for breast cancer patients
66. Late effects of adjuvant therapy for breast cancer
67. The clinical biochemistry of the menopause and hormone replacement therapy
68. The menopause transition
69. The normal menopause transition: An overview
70. Sexual function in the perimenopause
71. Hormone replacement therapy
72. Menopausal symptoms in breast cancer survivors
73. HRT and breast cancer: Managing menopausal sequelae in women at high risk of breast cancer
74. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients
75. Menopause: Plight of passage
76. Tamoxifen therapy in primary breast cancer, biology, efficacy, and side effects
77. Gynecologic complications associated with long-term adjutant therapy for breast cancer
78. Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer
79. Effects of cytotoxic therapy on sexuality and gonadal function
80. Decreased mortality in users of estrogen-replacement therapy
81. The controversy of hormone replacement therapy in breast cancer survivors
82. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy
83. Sexuality & cancer
84. Childbearing issues in breast cancer survivors
85. Cancer treatment induced menopause: Meaning for breast and gynecological cancer survivors
86. Consensus statement: Treatment of estrogen deficiency symptoms in women surviving breast cancer
87. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical implications
88. The risk of premature menopause induced by chemotherapy for early breast cancer
89. Effects of chemotherapy on fertility
90. Acute menopausal symptoms during adjuvant systemic treatment of breast cancer. A case control study